Private Equity
BDC Venture Capital and Accel-Rx Health Sciences Accelerator have formed a partnership to provide seed funding to Canadian health sciences startups. Accel-Rx, BDC and CDRD Ventures jointly will focus on company creation and the supply of resources needed for growth and development. The seed capital partnership with BDC will be the main funding mechanism, with selected Accel-Rx companies each receiving a $500,000 convertible note. The initial goal will be investments in up to four companies annually, with that number potentially increasing over time. Since 2012, BDC has provided $11 million in convertible notes funding to 74 information technology startups.
5 min read · 26 June 2014
BDC Venture Capital and Accel-Rx Health Sciences Accelerator have formed a partnership to provide seed funding to Canadian health sciences startups. Accel-Rx, BDC and CDRD Ventures jointly will focus on company creation and the supply of resources needed for growth and development. The seed capital partnership with BDC will be the main funding mechanism, with selected Accel-Rx companies each receiving a $500,000 convertible note. The initial goal will be investments in up to four companies annually, with that number potentially increasing over time. Since 2012, BDC has provided $11 million in convertible notes funding to 74 information technology startups.
5 min read · 26 June 2014
The U.S. Securities and Exchange Commission unveiled a one-year "tick size" pilot program to let some stocks trade in five-cent increments instead of one-penny increments.
2 min read · 25 June 2014
The U.S. Securities and Exchange Commission unveiled a one-year "tick size" pilot program to let some stocks trade in five-cent increments instead of one-penny increments.
2 min read · 25 June 2014
A Pennsylvania-based venture capital firm, TL Ventures, improperly claimed an exemption from the rules of the 2010 Dodd-Frank financial reform law requiring private equity firms to register with the agency as investment advisers, according to a recent ruling by the U.S. Securities and Exchange Commission.
3 min read · 25 June 2014
Canadian technology-focused fund-of-funds manager Teralys Capital has partnered with the Fonds de solidarité des travailleurs du Québec FTQ and BDC Venture Capital in backing U.S. life sciences venture capital firm Versant Ventures. Teralys committed $25 million to Versant, making its fifth investment in life sciences, an integral part of Teralys' and its partners' strategy to bolster the market ecosystem in Québec and across Canada. The three investor groups also plan to work with the firm on its recently launched drug discovery incubator Inception Sciences, located in Montréal. Northleaf Venture Catalyst Fund also announced a $10 million commitment to Versant.
6 min read · 24 June 2014
Canadian technology-focused fund-of-funds manager Teralys Capital has partnered with the Fonds de solidarité des travailleurs du Québec FTQ and BDC Venture Capital in backing U.S. life sciences venture capital firm Versant Ventures. Teralys committed $25 million to Versant, making its fifth investment in life sciences, an integral part of Teralys' and its partners' strategy to bolster the market ecosystem in Québec and across Canada. The three investor groups also plan to work with the firm on its recently launched drug discovery incubator Inception Sciences, located in Montréal. Northleaf Venture Catalyst Fund also announced a $10 million commitment to Versant.
6 min read · 24 June 2014
(Reuters) - Alberta Investment Management Corp (AIMCo), the $80 billion provincial pension manager, is steering clear of investments tied to existing roads, bridges and transmission lines as their growing popularity squeezes returns.
2 min read · 24 June 2014
Northleaf Venture Catalyst Fund (NVCF), which in January raised $218 million in its initial close, has made a $10 million commitment to U.S. venture capital firm Versant Ventures. NVCF, which is managed by Northleaf Capital Partners, said it wants to back Versant's contribution to Canada's life sciences ecosystem through its specialized model for launching and investing in early-stage companies. Versant has recently established incubators in Vancouver, Toronto and Montréal aimed at building companies launched by local academics and entrepreneurs. Other funds backed so far by NVCF include the latest offerings of Canadian firms Georgian Partners and XPV Capital Corp.
3 min read · 24 June 2014
U.S. life sciences-focused venture capital firm Versant Ventures has increased its presence in the Canadian market with the launch of a new biopharmaceutical incubator, Inception Sciences Montreal. The launch follows last year's establishment by Versant of Blueline Bioscience in Toronto and Inception Sciences Vancouver. The firm said that Inception Sciences Montreal adds a third Canada-based research site to its discovery engine to address the growing appetite of major pharmaceutical companies to enter into innovative venture-backed partnerships.
3 min read · 24 June 2014
